TIGIT and glioma: In early phase I clinical trials in patients with recurrent glioma (NCT04656535) and in patients with advanced solid tumors (NCT03628677), the safety and efficacy of co-blocking TIGIT and PD-1 using the mAbs AB154 and AB122 are being evaluated.